{
    "id": 3748,
    "name": "esophagus squamous cell carcinoma",
    "source": "DOID",
    "definition": "An esophageal carcinoma that derives_from epithelial squamous cells located_in the esophagus. [url:http\\://www.cancer.gov/cancertopics/types/esophageal]",
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        
    ],
    "termId": "DOID:3748",
    "evidence": [
        {
            "id": 1543,
            "approvalStatus": "Preclinical",
            "evidenceType": "Emerging",
            "efficacyEvidence": "In a preclinical study, overexpression of MED23 in esophageal squamous cell carcinoma cells inhibited growth, whereas downregulation promoted tumorigenecity in cells and animal models (PMID: 23625751).",
            "molecularProfile": {
                "id": 2651,
                "profileName": "MED23 over exp"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 3748,
                "name": "esophagus squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 1458,
                    "pubMedId": 23625751,
                    "title": "Downregulation of MED23 promoted the tumorigenecity of esophageal squamous cell carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23625751"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 2780,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LY294002 inhibited cell proliferation of esophagus squamous cell carcinoma cells expressing PIK3CA E545K (PMID: 18262558).",
            "molecularProfile": {
                "id": 2421,
                "profileName": "PIK3CA E545K"
            },
            "therapy": {
                "id": 1062,
                "therapyName": "LY294002",
                "synonyms": null
            },
            "indication": {
                "id": 3748,
                "name": "esophagus squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3478,
                    "pubMedId": 18262558,
                    "title": "PIK3CA mutation status in Japanese esophageal squamous cell carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18262558"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3607,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, OBP-801, in combination with 5-FU and radiation, enhanced growth inhibition of esophageal squamous carcinoma cells in culture (PMID: 24854104).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3173,
                "therapyName": "Fluorouracil + OBP-801",
                "synonyms": null
            },
            "indication": {
                "id": 3748,
                "name": "esophagus squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 3879,
                    "pubMedId": 24854104,
                    "title": "The novel HDAC inhibitor OBP-801/YM753 enhances the effects of 5-fluorouracil with radiation on esophageal squamous carcinoma cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24854104"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 3617,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, valproic acid enhanced the effectiveness of radiation in esophagus squamous cell carcinoma cell lines (PMID: 26135807).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1076,
                "therapyName": "Valproic acid",
                "synonyms": null
            },
            "indication": {
                "id": 3748,
                "name": "esophagus squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 3890,
                    "pubMedId": 26135807,
                    "title": "Inhibitory effects of valproic acid in DNA double-strand break repair after irradiation in esophageal squamous carcinoma cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26135807"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7513,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SHP099 inhibited ERK activation and reduced proliferation of EGFR-amplified esophageal squamous cell carcinoma cells in culture, and inhibited tumor growth in EGFR-amplified esophageal squamous cell carcinoma cell line xenograft models (PMID: 27362227).",
            "molecularProfile": {
                "id": 447,
                "profileName": "EGFR amp"
            },
            "therapy": {
                "id": 4504,
                "therapyName": "SHP099",
                "synonyms": null
            },
            "indication": {
                "id": 3748,
                "name": "esophagus squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6394,
                    "pubMedId": 27362227,
                    "title": "Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27362227"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7841,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with YM155 induced non-apoptotic cell death in esophageal squamous cell carcinoma (ESCC) cell lines in culture, and inhibited tumor growth in ESCC cell line xenograft models (PMID: 26090615).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3149,
                "therapyName": "YM155",
                "synonyms": null
            },
            "indication": {
                "id": 3748,
                "name": "esophagus squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 6510,
                    "pubMedId": 26090615,
                    "title": "YM155, a survivin suppressant, triggers PARP-dependent cell death (parthanatos) and inhibits esophageal squamous-cell carcinoma xenografts in mice.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26090615"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7879,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, esophagus squamous cell carcinoma cells harboring EGFR L861Q demonstrated resistance to treatment with Tarceva (erlotinib) in a cell viability assay (PMID: 27207775).",
            "molecularProfile": {
                "id": 1051,
                "profileName": "EGFR L861Q"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3748,
                "name": "esophagus squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6519,
                    "pubMedId": 27207775,
                    "title": "Afatinib against Esophageal or Head-and-Neck Squamous Cell Carcinoma: Significance of Activating Oncogenic HER4 Mutations in HNSCC.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27207775"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7881,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, esophageal squamous cell carcinoma cells harboring EGFR L861Q demonstrated resistance to treatment with Erbitux (cetuximab) in a cell viability assay (PMID: 27207775).",
            "molecularProfile": {
                "id": 1051,
                "profileName": "EGFR L861Q"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 3748,
                "name": "esophagus squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6519,
                    "pubMedId": 27207775,
                    "title": "Afatinib against Esophageal or Head-and-Neck Squamous Cell Carcinoma: Significance of Activating Oncogenic HER4 Mutations in HNSCC.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27207775"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7882,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gilotrif (afatinib) treatment resulted in apoptotic induction in esophagus squamous carcinoma cells harboring EGFR L861Q in culture and inhibited tumor growth in cell line xenograft models (PMID: 27207775).",
            "molecularProfile": {
                "id": 1051,
                "profileName": "EGFR L861Q"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3748,
                "name": "esophagus squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6519,
                    "pubMedId": 27207775,
                    "title": "Afatinib against Esophageal or Head-and-Neck Squamous Cell Carcinoma: Significance of Activating Oncogenic HER4 Mutations in HNSCC.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27207775"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7892,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, esophagus squamous cell carcinoma cells harboring EGFR amplification demonstrated resistance to Gilotrif (afatinib) in a cell viability assay (PMID: 27207775).",
            "molecularProfile": {
                "id": 447,
                "profileName": "EGFR amp"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3748,
                "name": "esophagus squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6519,
                    "pubMedId": 27207775,
                    "title": "Afatinib against Esophageal or Head-and-Neck Squamous Cell Carcinoma: Significance of Activating Oncogenic HER4 Mutations in HNSCC.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27207775"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7894,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, esophagus squamous cell carcinoma cells harboring EGFR amplification demonstrated resistance to Tarceva (erlotinib) in a cell viability assay (PMID: 27207775).",
            "molecularProfile": {
                "id": 447,
                "profileName": "EGFR amp"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3748,
                "name": "esophagus squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6519,
                    "pubMedId": 27207775,
                    "title": "Afatinib against Esophageal or Head-and-Neck Squamous Cell Carcinoma: Significance of Activating Oncogenic HER4 Mutations in HNSCC.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27207775"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7896,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, esophagus squamous cell carcinoma cells harboring EGFR amplification demonstrated resistance to Erbitux (cetuximab) in a cell viability assay (PMID: 27207775).",
            "molecularProfile": {
                "id": 447,
                "profileName": "EGFR amp"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 3748,
                "name": "esophagus squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6519,
                    "pubMedId": 27207775,
                    "title": "Afatinib against Esophageal or Head-and-Neck Squamous Cell Carcinoma: Significance of Activating Oncogenic HER4 Mutations in HNSCC.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27207775"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9159,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, a patient with esophagus squamous cell carcinoma treated with ADH-1 demonstrated a partial response, which was sustained for six months (PMID: 22280327).",
            "molecularProfile": {
                "id": 26758,
                "profileName": "CDH2 positive"
            },
            "therapy": {
                "id": 4916,
                "therapyName": "ADH-1",
                "synonyms": null
            },
            "indication": {
                "id": 3748,
                "name": "esophagus squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6940,
                    "pubMedId": 22280327,
                    "title": "Phase I clinical trial of Exherin (ADH-1) in patients with advanced solid tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22280327"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11799,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, imetelstat increased sensitivity of human esophageal squamous cell carcinoma cell lines to radiotherapy, resulting in increased apoptosis and decreased survival in culture, and increased apoptosis, decreased proliferation, and reduced tumor growth in mouse models (PMID: 28099140).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 6144,
                "therapyName": "Imetelstat + Radiotherapy",
                "synonyms": null
            },
            "indication": {
                "id": 3748,
                "name": "esophagus squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9792,
                    "pubMedId": 28099140,
                    "title": "Telomerase antagonist imetelstat increases radiation sensitivity in esophageal squamous cell carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28099140"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 13299,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, silencing of Atf1 expression enhanced the efficacy of paclitaxel in esophagus squamous cell carcinoma cells overexpressing Atf1, as demonstrated by inhibition of cell growth (PMID: 28912415).",
            "molecularProfile": {
                "id": 29070,
                "profileName": "ATF1 over exp"
            },
            "therapy": {
                "id": 1103,
                "therapyName": "Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 3748,
                "name": "esophagus squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11058,
                    "pubMedId": 28912415,
                    "title": "Targeting Overexpressed Activating Transcription Factor 1 (ATF1) Inhibits Proliferation and Migration and Enhances Sensitivity to Paclitaxel In Esophageal Cancer Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28912415"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13866,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Camrelizumab (SHR-1210) treatment resulted in an objective response rate of 33.3% (10/30, 1 complete response, 9 partial response) and a disease control rate of 56.7%, with a median progression free survival of 3.6 months in patients with advanced esophageal squamous cell carcinoma (PMID: 29358502; NCT02742935).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 6137,
                "therapyName": "Camrelizumab",
                "synonyms": null
            },
            "indication": {
                "id": 3748,
                "name": "esophagus squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 11322,
                    "pubMedId": 29358502,
                    "title": "Safety, Activity, and Biomarkers of SHR-1210, an Anti-PD-1 Antibody, for Patients with Advanced Esophageal Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29358502"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 13867,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Camrelizumab (SHR-1210) treatment resulted improved objective response rate (46.7%, 7/15 vs 11.1%, 1/9, p>0.05) and disease control rate (66.7%, 10/15 vs 33.3%, 3/9) in patients with CD274 (PD-L1)-positive advanced esophageal squamous cell carcinoma compared to patients with CD274 (PD-L1)-negative tumors (PMID: 29358502; NCT02742935).",
            "molecularProfile": {
                "id": 4746,
                "profileName": "CD274 positive"
            },
            "therapy": {
                "id": 6137,
                "therapyName": "Camrelizumab",
                "synonyms": null
            },
            "indication": {
                "id": 3748,
                "name": "esophagus squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11322,
                    "pubMedId": 29358502,
                    "title": "Safety, Activity, and Biomarkers of SHR-1210, an Anti-PD-1 Antibody, for Patients with Advanced Esophageal Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29358502"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15111,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, docetaxel treatment of esophageal squamous cell carcinoma cells overexpressing Deptor were resistant to response as demonstrated by a lack in decreased cell viability (PMID: 28267437).",
            "molecularProfile": {
                "id": 30746,
                "profileName": "DEPTOR over exp"
            },
            "therapy": {
                "id": 720,
                "therapyName": "Docetaxel",
                "synonyms": null
            },
            "indication": {
                "id": 3748,
                "name": "esophagus squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 12647,
                    "pubMedId": 28267437,
                    "title": "Different functions of DEPTOR in modulating sensitivity to chemotherapy for esophageal squamous cell carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28267437"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15112,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, epirubicin treatment of esophageal squamous cell carcinoma cells overexpressing Deptor were resistant to response as demonstrated by a lack in decreased cell viability (PMID: 28267437).",
            "molecularProfile": {
                "id": 30746,
                "profileName": "DEPTOR over exp"
            },
            "therapy": {
                "id": 1013,
                "therapyName": "Epirubicin",
                "synonyms": null
            },
            "indication": {
                "id": 3748,
                "name": "esophagus squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 12647,
                    "pubMedId": 28267437,
                    "title": "Different functions of DEPTOR in modulating sensitivity to chemotherapy for esophageal squamous cell carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28267437"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17875,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (KEYNOTE-181) that supported FDA approval, Keytruda (pembrolizumab) treatment as second-line therapy improved overall survival (OS) (9.3 vs 6.7 months, HR=0.69, p=0.0074) and 12-month OS rate (43% vs 20%) compared to chemotherapy in patients with esophagus squamous cell carcinoma with a CPS of 10% or higher (J Clin Oncol 37, no. 4_suppl (February 1 2019) 2-2;",
            "molecularProfile": {
                "id": 4746,
                "profileName": "CD274 positive"
            },
            "therapy": {
                "id": 1447,
                "therapyName": "Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 3748,
                "name": "esophagus squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15508,
                    "pubMedId": null,
                    "title": "Keytruda (pembrolizumab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514"
                },
                {
                    "id": 15847,
                    "pubMedId": null,
                    "title": "Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase III KEYNOTE-181 study.",
                    "url": "https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.4_suppl.2"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17695,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Keytruda (pembrolizumab) is included in guidelines as a preferred second-line therapy for patients with esophageal squamous cell carcinoma with CD274 (PD-L1) expression by CPS greater or equal to 10 (NCCN.org).",
            "molecularProfile": {
                "id": 4746,
                "profileName": "CD274 positive"
            },
            "therapy": {
                "id": 1447,
                "therapyName": "Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 3748,
                "name": "esophagus squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 19616,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, esophageal squamous cell carcinoma cells expressing SOX2 T116D were insensitive to MK2206-induced degradation of Sox2 and inhibition of tumor sphere formation in culture (PMID: 30894683).",
            "molecularProfile": {
                "id": 33218,
                "profileName": "SOX2 T116D"
            },
            "therapy": {
                "id": 816,
                "therapyName": "MK2206",
                "synonyms": null
            },
            "indication": {
                "id": 3748,
                "name": "esophagus squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 16192,
                    "pubMedId": 30894683,
                    "title": "AKT drives SOX2 overexpression and cancer cell stemness in esophageal cancer by protecting SOX2 from UBR5-mediated degradation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30894683"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19617,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, esophageal squamous cell carcinoma cells expressing SOX2 T116A were insensitive to MK2206-induced degradation of Sox2 and inhibition of tumor sphere formation in culture (PMID: 30894683).",
            "molecularProfile": {
                "id": 33217,
                "profileName": "SOX2 T116A"
            },
            "therapy": {
                "id": 816,
                "therapyName": "MK2206",
                "synonyms": null
            },
            "indication": {
                "id": 3748,
                "name": "esophagus squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 16192,
                    "pubMedId": 30894683,
                    "title": "AKT drives SOX2 overexpression and cancer cell stemness in esophageal cancer by protecting SOX2 from UBR5-mediated degradation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30894683"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19618,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, esophageal squamous cell carcinoma cells expressing SOX2 T116A were insensitive to MK2206-induced ubiquitination of Sox2 in culture (PMID: 30894683).",
            "molecularProfile": {
                "id": 33216,
                "profileName": "SOX2 K115R"
            },
            "therapy": {
                "id": 816,
                "therapyName": "MK2206",
                "synonyms": null
            },
            "indication": {
                "id": 3748,
                "name": "esophagus squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 16192,
                    "pubMedId": 30894683,
                    "title": "AKT drives SOX2 overexpression and cancer cell stemness in esophageal cancer by protecting SOX2 from UBR5-mediated degradation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30894683"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT01351103",
            "title": "A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1937,
                    "therapyName": "LGK974",
                    "synonyms": null
                },
                {
                    "id": 7468,
                    "therapyName": "LGK974 + Spartalizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01490749",
            "title": "Trial of XELOX Followed by Radiation Combined With Carboplatin and RAD001 for Esophageal Cancer",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1924,
                    "therapyName": "Carboplatin + Cetuximab + Everolimus + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01822613",
            "title": "Study of Safety and Efficacy of the Combination of LJM716 and BYL719 in Patients With Previously Treated Esophageal Squamous Cell Carcinoma (ESCC)",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2282,
                    "therapyName": "Docetaxel + Irinotecan + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 2283,
                    "therapyName": "Alpelisib + LJM716",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02013154",
            "title": "A Study of DKN-01 in Combination With Paclitaxel",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 6254,
                    "therapyName": "DKN-01 + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02389751",
            "title": "A Study of Ganetespib in Combination With Chemoradiation",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1092,
                    "therapyName": "Carboplatin",
                    "synonyms": null
                },
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 745,
                    "therapyName": "Ganetespib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02559687",
            "title": "Study of Pembrolizumab (MK-3475) in Previously-Treated Participants With Advanced Carcinoma of the Esophagus or Esophagogastric Junction (MK-3475-180/KEYNOTE-180)",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02564263",
            "title": "Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 2282,
                    "therapyName": "Docetaxel + Irinotecan + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02710396",
            "title": "Genetic Predictors of Benefit to Pembrolizumab",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2105,
                    "therapyName": "Carboplatin + Pembrolizumab + Pemetrexed",
                    "synonyms": null
                },
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 5591,
                    "therapyName": "Carboplatin + Nab-paclitaxel + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02971956",
            "title": "A Phase II Study of Pembrolizumab in Refractory Advanced Esophageal Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03132922",
            "title": "MAGE-A4c1032T for Multi-Tumor",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7280,
                    "therapyName": "ADP-A2M4 cells",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03143153",
            "title": "A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin (CheckMate 648)",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1627,
                    "therapyName": "Ipilimumab + Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 1833,
                    "therapyName": "Cisplatin + Fluorouracil",
                    "synonyms": null
                },
                {
                    "id": 5799,
                    "therapyName": "Cisplatin + Fluorouracil + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03165994",
            "title": "APX005M With Concurrent Chemoradiation for Resectable Esophageal and Gastroesophageal Junction Cancers",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5797,
                    "therapyName": "APX005M + Carboplatin + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03189719",
            "title": "First-line Esophageal Carcinoma Study With Chemo vs. Chemo Plus Pembrolizumab (MK-3475-590/KEYNOTE-590)",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1833,
                    "therapyName": "Cisplatin + Fluorouracil",
                    "synonyms": null
                },
                {
                    "id": 6051,
                    "therapyName": "Cisplatin + Fluorouracil + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03261947",
            "title": "A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 7279,
                    "therapyName": "TAK-931",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03430843",
            "title": "A Study of BGB-A317 Versus Chemotherapy as Second Line Treatment in Patients With Advanced Esophageal Squamous Cell Carcinoma",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 720,
                    "therapyName": "Docetaxel",
                    "synonyms": null
                },
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 5871,
                    "therapyName": "BGB-A317",
                    "synonyms": null
                },
                {
                    "id": 1074,
                    "therapyName": "Irinotecan",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03610711",
            "title": "REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric Cancer (REACTION)",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4197,
                    "therapyName": "Nivolumab + Relatlimab",
                    "synonyms": null
                },
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03694249",
            "title": "Ifetroban in Treating Patients With Malignant Solid Tumors at High Risk of Metastatic Recurrence",
            "phase": "Phase II",
            "recruitment": "Suspended",
            "therapies": [
                {
                    "id": 9193,
                    "therapyName": "Ifetroban sodium",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04000529",
            "title": "Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8507,
                    "therapyName": "Spartalizumab + TNO155",
                    "synonyms": null
                },
                {
                    "id": 8522,
                    "therapyName": "Ribociclib + TNO155",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04032704",
            "title": "A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3615,
                    "therapyName": "SGN-LIV1A",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04060342",
            "title": "GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8693,
                    "therapyName": "GB1275",
                    "synonyms": null
                },
                {
                    "id": 8694,
                    "therapyName": "GB1275 + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 8695,
                    "therapyName": "GB1275 + Gemcitabine + Nab-paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04145622",
            "title": "Study of DS-7300a in Participants With Advanced Solid Malignant Tumors",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9154,
                    "therapyName": "DS-7300a",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04152018",
            "title": "Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8931,
                    "therapyName": "PF-06801591 + PF-06940434",
                    "synonyms": null
                },
                {
                    "id": 8930,
                    "therapyName": "PF-06940434",
                    "synonyms": null
                }
            ]
        }
    ]
}